In this OncLive® News Network program, Dr. Mark Socinski and Dr. Susan Scott discuss the evolving treatment landscape for patients with EGFR-mutant non-small cell lung cancer (NSCLC), highlighting recent advances that are reshaping treatment selection across the continuum of care. The discussion explores emerging clinical evidence supporting first-line treatment strategies, interpretation of progression-free and overall survival outcomes, and considerations for treatment sequencing following disease progression. Drs. Socinski and Scott also examine patient- and disease-specific factors that influence therapeutic decision-making, approaches to managing treatment-related adverse events, and practical strategies for maintaining treatment continuity in clinical practice. Additional topics include mechanisms of resistance, molecular reassessment at progression, the role of emerging therapies, multidisciplinary care, and the impact of treatment complexity, access, and financial burden on patient-centered management of EGFR-mutant NSCLC, with an emphasis on translating evolving evidence into everyday clinical practice.
This introductory segment provides an overview of the evolving treatment landscape for EGFR-mutant non-small cell lung cancer (NSCLC) and establishes the key themes for the discussion.
This segment explores how treatment decisions for EGFR-mutant non-small cell lung cancer (NSCLC) are increasingly individualized despite the availability of combination frontline therapies.
